环硅酸锆钠联合肾素-血管紧张素-醛固酮系统抑制剂治疗慢性肾脏病的机制和效果的研究进展  

Research progress on the mechanism and effect of Sodium Zirconium Cyclosilicate combined with renin-angiotensin-aldosterone system inhibitors in treatment of chronic kidney disease

作　　者：岳佳丽 海光 雷卓颖 王丽君 YUE Jiali;HAI Guang;LEI Zhuoying;WANG Lijun(School of Basic Medicine,Harbin Medical University,Heilongjiang Province,Harbin 150081,China)

机构地区：[1]哈尔滨医科大学基础医学院,黑龙江哈尔滨150081

出　　处：《中国医药导报》2024年第16期188-190,共3页China Medical Herald

基　　金：国家自然科学基金资助项目(31971064);黑龙江省自然科学基金项目(YQ2020C042)。

摘　　要：肾素-血管紧张素-醛固酮系统抑制剂(RAASi)能够延缓慢性肾脏病(CKD)的进展,但常因易引起高钾血症而受到限制。而新型口服钾结合剂环硅酸锆钠(SZC)与RAASi联合治疗可快速降低CKD患者血钾水平,并改善CKD患者肾功能。然而,两者联合治疗CKD的作用机制尚未完全阐明。因此,本文主要讨论SZC与RAASi在单独使用或联合使用时对CKD的作用机制及治疗效果,旨在为CKD患者提供更优化的治疗方案。Renin-angiotensin-aldosterone system inhibitors(RAASi)can delay the progression of chronic kidney disease(CKD),but are often limited by their susceptibility to hyperkalemia.A new oral potassium binder,Sodium Zirconium Cyclosilicate(SZC),combined with RAASi,can rapidly reduce the serum potassium level and improve kidney function in CKD patients.However,the action mechanism of the combined treatment of CKD has not been fully elucidated.Therefore,this paper mainly discusses the mechanism and therapeutic effect of SZC and RAASi on CKD when used alone or in combination,aiming to provide a more optimized treatment plan for patients with CKD.

关 键 词：环硅酸锆钠 肾素-血管紧张素-醛固酮系统抑制剂 慢性肾脏病 高钾血症 

分 类 号：R453.9[医药卫生—治疗学] R692[医药卫生—临床医学]